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EDITORIAL
Conflict of interest
In most American and some UK journals it is now cus-
tomary for authors to be required to state whether or
not there is a conflict of interest between what they
have written and any sponsorship, actual or implied,
that may be perceived to have been obtained from any
agency involved in any product or policy that they are
discussing or reporting upon. I wondered, when ‘con-
flict of interest’ policies were first developed, whether
we should adopt similar mechanisms for ‘Seizure’.
Initially I thought this unnecessary since much con-
flict of interest is transparent (reports of drug trials,
for instance, which, anyway, are independently refer-
eed) and, since the number of opinion leaders in the
epilepsy world is small, they would be known to the
Editor who could prevent obvious abuses.
Recently, however, I have changed my mind, partly
because I have seen how the policy works, partly be-
cause of a letter in our correspondence column, but
also because of several recent experiences. In describ-
ing these experiences I am not going to name the agen-
cies involved.
A short while ago I was asked, as were several
UK opinion leaders, to take part in a series of (paid)
presentations about a new drug whose uses and prop-
erties, for a variety of reasons, are little known in the
UK. My presentation would be based on my assess-
ment of the relevant literature (which included taking
part in a very instructive Advisory Board in the United
States) and on my early experience of the drug (but
not on personal trial experience). It was to be, as far
as I could determine, an exposition of what, having
weighed up the evidence, my clinical practice with the
drug would be (indeed I used as the basis for it the
instruction leaflet on the drug I had already prepared
for my junior medical and nursing staff on the use
and indications for the new drug in our clinic). Initial
discussion about the meeting was with a medical com-
munication company (who behaved entirely properly
throughout) and was merely concerned with preparing
an abstract and developing the necessary slide ma-
terial. I was looking forward to the actual meeting
since, as is now common in such meetings, there were
to be other participants (speaking not about the drug
itself but on other aspects of epilepsy) and I had in-
vited two speakers whom I had particularly wanted
to hear.
However, shortly before the meeting I received a fax
of my abstract, scribbled over with comments which
I can only conclude had come from someone in the
company itself inviting me to shade my opinion, not
say some of the things I was going to say and em-
phasize points that I think would have made the piece
factually wrong. I could only refuse, resign my chair-
manship of the meeting and not give my presentation,
which, I understand, was given by someone else. This
was an easy decision to make, and I am sure was the
right one. But it led me to wonder, uneasily, about two
things. Had my colleague, who had taken over, said the
things that I had been asked to say and felt I could not:
had my colleagues who gave their presentation in var-
ious parts of the country also, unwittingly, been com-
promised into giving the company view?
This lead me to contemplate the number of satel-
lite symposia at many conferences I have attended
(most with a remarkably similar Faculty) usually with
a bright catchy name and an optimistic review of the
particular company’s new drug. It would be difficult
to judge how biased such presentations would be, but
a conflict of interest statement by each speaker might
be illuminating, although, since such presentations are
usually held in exotic locations, the combined effects
of jet lag, travellers diarrhoea and exuberant hospital-
ity has usually blunted the audience’s critical faculties.
Recently ‘Seizure’ received a manuscript relating to
a head to head trial comparing two newer drugs: there
was no placebo arm to the trial. Statistically, as the pa-
per admitted, the trial was under powered. And yet the
paper very heavily promoted one of the drugs over the
other (although both seemed equally effective within
the limited significance testing that an under powered
trial can provide). Perusal of the manuscript revealed
that the study had probably been funded by the particu-
lar company whose drug appeared to be advantageous.
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With two colleagues I have recently been reviewing
the literature relating to the putative relationship be-
tween epilepsy, its treatment and the polycystic ovary
syndrome. The literature is muddled and confused and
open to different interpretations, particularly because
the epilepsy world, spurred on by commercial inter-
ests, has blundered into an area that was already con-
troversial (since the concept of the polycystic ovary
syndrome is changing from a structural one to a hor-
monal/metabolic one) and the syndrome has legiti-
mately different definitions in the USA and the UK.
Thus it is possible to make apparently contradictory
statements about its prevalence in epilepsy and its
association with the use of a particular drug with-
out necessarily being wrong, but still being potentially
misleading. So, in reading any review of the subject, at
the moment, in the epilepsy literature, one has to ask
‘who sponsored this?’ Our own review will appear in
‘Seizure’ shortly, hopefully unbiased, but will contain
a statement of possible conflict of interest.
And, as Editor, I am going to have to ask you to
do the same. Our instructions to authors will be modi-
fied to ask our authors, routinely, to state any potential
conflict of interest between any possible commercial
or governmental sponsorship and the piece in ques-
tion. Conflict of interest might arise if the author had
been paid to write the piece, if he or she was giving
their name to a piece ‘ghosted’ by someone else, if
the piece of research had been sponsored by a govern-
ment or a company, or if the authors’ department or
research programme was dependant on sponsorship or
donation from a relevant company or the writer had
shares in the company (unlikely in the UK). If you do
not make a declaration, we may ask you to do so. And,
although it is probably impossible to totally eradicate
ghost writing—much as journals dislike it—if you are
part, say, of a focus group or research team whose de-
liberations or research is being written up by a third
party: do read it very carefully before you put your
name to it and ensure it accurately reflects your views
and ask ‘Is there a possible conflict of interest here?’
Tim Betts
Editor
CONFLICT OF INTEREST
Journals worldwide are dependent on advertizing rev-
enue and so, potentially, are not completely free from
conflict of interest. The main conflict of interest in this
editorial is that I may have offended several parties:
but I think it had to be written. Blatant commercial
pressure is not good for us, our readers, the health ser-
vices using public whom we serve nor, least of all, for
the commercial company itself.
